Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Raw Materials: 2020-2024

Historic Raw Materials for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $17.0 million.

  • Maravai Lifesciences Holdings' Raw Materials fell 3.81% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year decrease of 3.81%. This contributed to the annual value of $17.0 million for FY2024, which is 12.22% down from last year.
  • As of FY2024, Maravai Lifesciences Holdings' Raw Materials stood at $17.0 million, which was down 12.22% from $19.3 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Raw Materials registered a high of $19.7 million during FY2021, and its lowest value of $11.1 million during FY2020.
  • Moreover, its 3-year median value for Raw Materials was $17.0 million (2024), whereas its average is $16.6 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Raw Materials spiked by 77.52% in 2021 and then plummeted by 31.63% in 2022.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Raw Materials stood at $11.1 million in 2020, then skyrocketed by 77.52% to $19.7 million in 2021, then tumbled by 31.63% to $13.5 million in 2022, then soared by 43.39% to $19.3 million in 2023, then fell by 12.22% to $17.0 million in 2024.